Clovis Oncology, Inc.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Private
- Established
- 2009-01-01
- Employees
- 413
- Market Cap
- -
- Website
- http://clovisoncology.com
Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients
Phase 1
Terminated
- Conditions
- Locally Advanced or Metastatic Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2012-02-06
- Last Posted Date
- 2020-08-04
- Lead Sponsor
- Clovis Oncology, Inc.
- Target Recruit Count
- 612
- Registration Number
- NCT01526928
- Locations
- ๐บ๐ธ
University of California, Irvine, Orange, California, United States
๐บ๐ธUniversity of Maryland, Baltimore, Maryland, United States
๐บ๐ธUCLA Health System, Santa Monica, California, United States
Safety and Pharmacokinetic Profiles of Two Formulations of CO-1.01 in Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: CO-1.01 Formulation B (Aqueous suspension containing 30 mg/mL of drug solubilized in purified phospholipids)Drug: CO-1.01 Formulation A (Aqueous suspension containing 15 mg/mL of drug solubilized in purified phospholipids)
- First Posted Date
- 2011-07-13
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Clovis Oncology, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT01392976
- Locations
- ๐ณ๐ฑ
The Netherlands Cancer Institute, Amsterdam, Netherlands
๐ณ๐ฑMaastricht University Medical Center, Maastricht, Netherlands
๐ณ๐ฑUniversity Medical Center Utrecht, Utrecht, Netherlands
Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma
- First Posted Date
- 2010-11-03
- Last Posted Date
- 2019-03-11
- Lead Sponsor
- Clovis Oncology, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT01233375
- Locations
- ๐บ๐ธ
Piedmont Healthcare Research Institute (PHRI), Atlanta, Georgia, United States
๐บ๐ธMedical College of Wisconsin, Milwaukee, Wisconsin, United States
๐บ๐ธUniversity of Miami, Miami, Florida, United States
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)
Phase 2
Completed
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2010-05-17
- Last Posted Date
- 2014-04-17
- Lead Sponsor
- Clovis Oncology, Inc.
- Target Recruit Count
- 367
- Registration Number
- NCT01124786
- Locations
- ๐บ๐ธ
Newport Cancer Care Medical, Newport Beach, California, United States
๐บ๐ธWhite Memorial Medical Center, Los Angeles, California, United States
๐ฆ๐บSaint Vincent's Hospital, Fitzroy, Victoria, Australia
ยฉ Copyright 2025. All Rights Reserved by MedPath